About: Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.95 (-2.94%)
RADX NASDAQ Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited American Depositary Shares share price
Atividade de preço de RADX
Último preço
$ 0,950
Variação (24h)
-0,03 USD (2,94%)
Volume
15.76K
Volume (média 4 sem.)
-
Abertura
$ 0,95
Variação do dia
$ 0,91 - $ 0,99
Fechamento anterior
$ 0,98
Último negócio
22 Oct, 8:00 pm GMT+0
Atrasado
22 Oct, 8:00 pm GMT+0
RADX price performance
Atrasado
22 Oct, 8:00 pm GMT+0
quote.marketSignals